Ajinomoto Bio-Pharma Services, a provider of biopharmaceutical contract development and manufacturing services, announced that the U.S. FDA has approved the first commercial drug manufactured leveraging Aji Bio-Pharma’s AJIPHASE production process. Originally developed for peptide synthesis, the AJIPHASE synthesis technology has expanded to include oligonucleotide production. A hybrid of traditional solid phase and solution phase synthesis, using an anchor in place of a resin, AJIPHASE is a ...